Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2019-10-14 Capital/Financing Update
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million
Capital/Financing Update Classification · 98% confidence The document explicitly announces a 'notice to an extra general meeting' which is proposed to authorize a 'rights issue of approximately SEK 400 million'. It details the use of proceeds, shareholder commitments (Arwidsro), and a financing commitment to repay a convertible loan. This content directly relates to capital structure changes, fundraising, and shareholder voting authorization for a specific corporate action (the rights issue). This aligns best with the 'Capital/Financing Update' (CAP) category, as the primary focus is the proposed rights issue and associated financing commitments, rather than just the notice of the meeting itself (which would lean towards PSI or AGM-R, but the financial action is dominant). Since it details the financing plan and capital change proposal, CAP is the most accurate fit.
2019-10-14 English
Kallelse till extra bolagsstämma i Oasmia Pharmaceutical AB
AGM Information Classification · 98% confidence The document is explicitly titled "Kallelse till extra bolagsstämma i Oasmia Pharmaceutical AB" (Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB). It details the date, time, location, registration procedures, proposed agenda items (including a key proposal for authorizing the board to issue new shares via a rights issue), and shareholder rights information for an upcoming meeting. This content perfectly matches the definition of materials related to a General Meeting, specifically a notice calling for one. The closest specific category is AGM-R (AGM Information), although this is an *Extraordinary* General Meeting (EGM). Since AGM-R covers general meeting materials, it is the most appropriate fit among the provided options, as there is no specific EGM code. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Proxy Statement (PSI), but rather the formal notice convening the meeting.
2019-10-14 Swedish
Notice of extraordinary general meeting in Oasmia Pharmaceutical AB
AGM Information Classification · 98% confidence The document is explicitly titled "Notice of extraordinary general meeting in Oasmia Pharmaceutical AB" and details the date, time, location, registration procedures, and the proposed agenda for this meeting. The agenda includes items like the election of the chairman and a resolution regarding authorization for a preferential rights issue. This content directly corresponds to the notification and materials associated with a shareholder meeting, specifically an Extraordinary General Meeting (EGM). While the document discusses a resolution (which might be voted on at an AGM), the primary purpose and format of this announcement is the formal notice for the meeting itself. The closest category is AGM-R (AGM Information), as EGMs share similar notification structures with AGMs, focusing on shareholder assembly and voting matters. It is not a DEF 14A (Remuneration) or DVA (Voting Results), as it is the notice *before* the vote.
2019-10-14 English
The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled a "PRESS RELEASE" dated October 14, 2019. The core subject is the proposal by the Board of Directors to authorize a rights issue of approximately SEK 400 million, contingent upon an extra general meeting resolution. This directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it mentions an Extra General Meeting, the primary focus and announcement is the proposed financing action, not the voting results (DVA) or the AGM materials themselves (AGM-R). It is not a full financial report (10-K or IR) or a simple dividend notice (DIV).
2019-10-14 English
Styrelsen i Oasmia föreslår en företrädesemission om cirka 400 MSEK
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) and announces that the Board of Directors proposes a rights issue (företrädesemission) of approximately 400 MSEK, contingent on a resolution at an upcoming Extraordinary General Meeting (extra bolagsstämma). This type of announcement, detailing a significant financing activity (issuing new shares to raise capital), directly corresponds to the definition of a Capital/Financing Update. It is not a full annual report (10-K), an earnings release (ER), or a simple notice of dividend (DIV). Since it is a formal announcement detailing the structure and purpose of a capital raise, the most appropriate code is CAP.
2019-10-14 Swedish
Årsstämma i Oasmia Pharmaceutical AB den 26 september 2019
AGM Information Classification · 98% confidence The document is a summary of the decisions made during the Annual General Meeting (AGM) of Oasmia Pharmaceutical AB held on September 26, 2019. It details the approval of financial statements, dividend decisions, board member elections, and amendments to the articles of association. While it contains a link to a full communique, the text itself provides the core results and resolutions of the meeting, which aligns with the definition of AGM Information (AGM-R).
2019-09-26 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.